Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been given an average recommendation of “Moderate Buy” by the five analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $4.80.

Several analysts have issued reports on KPTI shares. Royal Bank of Canada reissued an “outperform” rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Robert W. Baird cut their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Finally, StockNews.com upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th.

Karyopharm Therapeutics Stock Up 1.3 %

Shares of NASDAQ:KPTI opened at $0.85 on Friday. The firm has a fifty day simple moving average of $0.79 and a two-hundred day simple moving average of $0.95. Karyopharm Therapeutics has a 52 week low of $0.62 and a 52 week high of $1.95. The stock has a market capitalization of $105.67 million, a P/E ratio of -0.67 and a beta of 0.20.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, August 6th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.09. The company had revenue of $42.79 million for the quarter, compared to the consensus estimate of $36.07 million. On average, analysts expect that Karyopharm Therapeutics will post -0.93 earnings per share for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 DIFC Ltd bought a new stake in shares of Karyopharm Therapeutics in the second quarter valued at about $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth approximately $143,000. Acadian Asset Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth approximately $167,000. Exchange Traded Concepts LLC increased its holdings in Karyopharm Therapeutics by 34.9% during the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after buying an additional 56,613 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in Karyopharm Therapeutics in the second quarter worth approximately $494,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).